[작성자:] Ashley Zhu
-
Clinical Utility of Genetic Testing for Rare Diseases
3billion has prepared an on-demand webinar – “Clinical Utility of Genetic Testing for Rare Diseases.”Join us for the webinar and gain insights as nationally renowned doctors/experts will speak about actual rare disease diagnosis cases! *The webinar is held in Ukrainian. What content does the webinar cover?– Status of rare diseases and genetic testing in Ukraine– Clinical utility of NGS genetic…
-
Advancements and Applications of Whole-Exome Sequencing in Pediatric Neurology
In this webinar, with a clinical genetic experts from 3billion and pediatric neurologist from Thiland, get insight insight into the use of genetic testing in pediatric neurology. What content does the webinar cover?– Types and characteristics of genetic tests that can be used in real-life pediatric neurology cases– Why genetic testing is useful, especially in pediatrics–…
-
3 Proven Actions You Should Take for Undiagnosed Patients After Exome Sequencing
What Should You Do If Your Patient Remains Undiagnosed After Exome Sequencing? Diagnosing patients with rare or undiagnosed conditions poses significant challenges for medical professionals. Medical professionals are left with many questions when initial genetic tests like Exome Sequencing (ES) do not yield precise results. This guide outlines three essential actions medical staff should take…
-
The Future of Genetic Diagnostics: NGS, Reanalysis, and Collaboration
Next-generation sequencing has revolutionized genetic research by allowing for the rapid and cost-effective sequencing of entire genomes. This technological leap has not only facilitated initial gene discovery but also enabled continuous reanalysis of genetic data. The dynamic field of genetic medicine has greatly benefited from continuous reanalysis of genetic data, leading to the discovery of…
-
Case of Cardio-facio-cutaneous syndrome: The Critical Role of Genetic Testing
Rare diseases often present unique challenges in the medical field, not least of which is obtaining a timely and accurate diagnosis. For numerous patients and families, navigating the stages of the diagnostic odyssey to understand and manage a rare disease condition is marked by uncertainties, frequent misdiagnoses, and, often, prolonged years of seeking answers. However, the advent of genetic…
-
Have You Been Left Undiagnosed After a Genetic Test?
It can be quite discouraging to discover that you have an undiagnosed medical condition after undergoing genetic testing. However, with the rapid advancements in genetic research, reanalysis offers new hope. Recent studies indicate that reanalyzing genetic data can significantly improve diagnostic rates, reflecting ongoing advancements in the field. A 2019 study revealed that reanalysis within five years…
-
3billion Announced the Winners of the End the Diagnostic Odyssey Grant
3billion recently announced the first recipients of the End The Diagnostic Odyssey Grant. The grant was offering a total of up to $1,000,000 of whole exome sequencing (WES) services provided by 3billion to be distributed among the winners. The grant application was open to all physicians and researchers looking to help end the diagnostic odyssey of…
-
3billion meet European doctors and researchers of rare disease diagnostics by participating in ESHG 2022
3billion is participating in the ‘European Society of Human Genetics Annual Conference(ESHG 2022)’ to in Vienna, Austria from June 11 to 14 (local time). ESHG is one of the world’s most renowned conferences in the genomics field, and will be held as an online/offline hybrid event this year, which was held only as an online…
-
3billion receives accreditation from the CDPH as a clinical laboratory
On April 6th, 3billion announced that it had received accreditation from the California Department of Public Health (CDPH) as a clinical laboratory in the United States. This certification is separate from CLIA (Clinical Laboratory Improvement Amendments) and is managed by the California Department of Public Health under the state of California. 3billion received CLIA certification three months…
-
3billion makes genetic test for rare diseases affordable
3billion announces that for a service fee of $699, it can diagnose over 7,000 rare diseases by examining patients’ genetic data. The company has over 4,000 actual diagnosis results and is expected to exceed 10,000 diagnoses this year. 3billion CEO Changwon Keum said: By adding proprietary, streamlined interpretation software, we can analyze 100,000+ variants in…